The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

Infections with the hepatitis E virus often go unnoticed because they cause no symptoms. However, in patients with a weakened immune system or existing liver damage and also in pregnant women, the ...

The Zika virus builds tiny tunnels, called tunneling nanotubes, to stealthily transport material needed to infect nearby cells, including in placental cells, according to a team of researchers from ...

To become infectious, HIV has to undergo a maturation process. This involves the HIV-1 protease (a viral enzyme), that cuts up Gag into six smaller proteins including the capsid protein and the matrix ...

Latus’ other lead gene therapy uses its AAV-Ep+ capsid to target ependymal cells as well as neurons. Ependymal cells secrete proteins into the cerebrospinal fluid. Co-opting this function ...

Krol, M. A., et al., RNA-controlled polymorphism in the in vivo assembly of 180-subunit and 120-subunit virions from a single capsid protein. Proceedings of the National Academy of Sciences of the ...

how do the capsid proteins identify their genome for encapsidation, and 3) are specific nuclear sites used as 'workbenches' to couple viral DNA replication with capsid assembly. Our study of human ...

Viral proteins with sugars attached to them are ... These viruses have only the capsid surrounding their genetic material. A virus budding from a host cell membrane. This sequence of steps forms ...

Lenacapavir 463.5mg/1.5mL (309mg/mL); soln for SC inj; preservative-free. Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between ...